Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 15.69% is in line with its 1-year average of 15.64%, around the middle of its 1-year range (13.85%–16.84%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 16.84%.
GROSS MARGIN
15.69%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-61.92%
vs the sector median at left
Market Cap
$656.59M
Gross Margin
91.05%
TTM Avg
-190849.07%
3Y Avg
-96132.87%
5Y Avg
-64176.88%
Market Cap
$666.95M
Gross Margin
100.27%
TTM Avg
50.13%
3Y Avg
25.07%
5Y Avg
10.71%
Market Cap
$673.41M
Gross Margin
78.85%
TTM Avg
82.67%
3Y Avg
82.58%
5Y Avg
83.02%
Market Cap
$638.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$681.27M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$634.30M
Gross Margin
84.52%
TTM Avg
76.56%
3Y Avg
85.05%
5Y Avg
87.20%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | 15.69% | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 91.05% | -190849.07% | -96132.87% | -64176.88% |
| Annexon, Inc. (ANNX)vs › | $660.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 100.27% | 50.13% | 25.07% | 10.71% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 78.85% | 82.67% | 82.58% | 83.02% |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| Verastem, Inc. (VSTM)vs › | $681.02M | 86.69% | 91.43% | 70.72% | 74.12% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 0.00% | 0.00% | 25.00% | 33.33% |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 84.52% | 76.56% | 85.05% | 87.20% |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -58.05% | 20.98% | 10.49% | 14.13% |
Gross Margin
15.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 16.84% |
| 2026-03-31 | 15.81% |
| 2025-12-31 | 16.04% |
| 2025-09-30 | 13.85% |
